AHR Stock Analysis: American Healthcare REIT | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 12.313m USD | 12M Return: 37.6% | US3981823038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 149M
Qual. Beats: 0
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 2.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
American Healthcare REIT, Inc. (NYSE: AHR) is a self-managed real estate investment trust headquartered in Irvine, California, that owns and operates a diversified portfolio of clinical healthcare properties across the United States, the United Kingdom, and the Isle of Man. Its portfolio spans senior housing, skilled nursing facilities (SNFs), outpatient medical (MOB) buildings, and other healthcare-related real estate. The company operates its senior housing assets under the RIDEA (REIT Investment Diversification and Empowerment Act) structure, which enables REITs to lease properties to taxable REIT subsidiaries and participate in operating performance, blending real estate ownership with operational upside.
In addition to owning and operating healthcare properties, AHR originates and acquires secured real estate loans and may pursue other opportunistic real estate-related investments. The REIT selectively develops healthcare assets, targeting income-generating properties, and has elected REIT tax treatment under the U.S. Internal Revenue Code, which generally requires distributing at least 90% of taxable income to shareholders. As a Health Care REIT within the Real Estate sector, AHR is positioned to benefit from long-term demographic tailwinds such as aging populations, though the asset class typically carries higher operational complexity and reimbursement risk compared to other property types.
- Senior housing occupancy recovery accelerates RIDEA NOI growth
- Skilled nursing Medicaid reimbursement rates face state budget pressure
- Interest rate cuts compress borrowing costs and expand property acquisition pipeline
| Net Income: 121.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 1.19 > 1.0 |
| NWC/Revenue: -28.98% < 20% (prev -21.67%; Δ -7.31% < -1%) |
| CFO/TA 0.06 > 3% & CFO 369.0m > Net Income 121.0m |
| Net Debt (1.54b) to EBITDA (447.2m): 3.43 < 3 |
| Current Ratio: 0.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (190.7m) vs 12m ago 18.35% < -2% |
| Gross Margin: 14.94% > 18% (prev 20.62%; Δ -5.68% > 0.5%) |
| Asset Turnover: 49.01% > 50% (prev 47.70%; Δ 1.31% > 0%) |
| Interest Coverage Ratio: 2.27 > 6 (EBIT TTM 176.2m / Interest Expense TTM 77.6m) |
| A: -0.13 (Total Current Assets 156.9m - Total Current Liabilities 882.0m) / Total Assets 5.70b |
| B: -0.28 (Retained Earnings -1.60b / Total Assets 5.70b) |
| C: 0.03 (EBIT TTM 176.2m / Avg Total Assets 5.11b) |
| D: 1.88 (Book Value of Equity 3.69b / Total Liabilities 1.96b) |
| Altman-Z'' = 0.46 = B |
| DSRI: 0.88 (Receivables 229.6m/224.1m, Revenue 2.50b/2.15b) |
| GMI: 1.38 (GM 20.62% / 14.94%) |
| AQI: 0.21 (AQ_t 0.18 / AQ_t-1 0.85) |
| SGI: 1.16 (Revenue 2.50b / 2.15b) |
| TATA: -0.04 (NI 121.0m - CFO 369.0m) / TA 5.70b) |
| Beneish M = -3.14 (Cap -4..+1) = AA |
As of September 02, 2026, the stock is trading at USD 56.54 with a total of 3,166,306 shares traded. Over the past week, the price has changed by -0.89%, over one month by +2.58%, over three months by +20.29% and over the past year by +37.57%.
Current recommended Stop Loss: 54.30 (which is 4% or 1.8 ATR below the current price).
American Healthcare REIT has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AHR.
- StrongBuy: 4
- Buy: 4
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.7 | 12.6% |
P/E Trailing = 83.0588
P/E Forward = 61.7284
P/S = 4.9155
P/B = 3.3728
Revenue TTM = 2.50b USD
EBIT TTM = 176.2m USD
EBITDA TTM = 447.2m USD
Long Term Debt = 892.7m USD (from longTermDebt, last quarter)
Short Term Debt = 549.9m USD (from shortTermDebt, last quarter)
Debt = 1.69b USD (from shortLongTermDebtTotal, last quarter) + Leases 124.9m
Net Debt = 1.54b USD (calculated: Debt 1.69b - CCE 156.9m)
Enterprise Value = 13.8b USD (12.3b + Debt 1.69b - CCE 156.9m)
Interest Coverage Ratio = 2.27 (Ebit TTM 176.2m / Interest Expense TTM 77.6m)
EV/FCF = 52.89x (Enterprise Value 13.8b / FCF TTM 261.8m)
FCF Yield = 1.89% (FCF TTM 261.8m / Enterprise Value 13.8b)
FCF Margin = 10.47% (FCF TTM 261.8m / Revenue TTM 2.50b)
Net Margin = 4.84% (Net Income TTM 121.0m / Revenue TTM 2.50b)
Gross Margin = 14.94% ((Revenue TTM 2.50b - Cost of Revenue TTM 2.13b) / Revenue TTM)
Gross Margin QoQ = -1.04% (prev 21.30%)
Tobins Q-Ratio = 2.43 (Enterprise Value 13.8b / Total Assets 5.70b)
Interest Expense / Debt = 4.59% (Interest Expense 77.6m / Debt 1.69b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 139.2m (EBIT 176.2m * (1 - 21.00%))
Current Ratio = 0.18 (Total Current Assets 156.9m / Total Current Liabilities 882.0m)
Debt / Equity = 0.46 (Debt 1.69b / totalStockholderEquity, last quarter 3.69b)
Debt / EBITDA = 3.43 (Net Debt 1.54b / EBITDA 447.2m)
Debt / FCF = 5.86 (Net Debt 1.54b / FCF TTM 261.8m)
Total Stockholder Equity = 3.29b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.37% (Net Income 121.0m / Total Assets 5.70b)
RoE = 3.67% (Net Income TTM 121.0m / Total Stockholder Equity 3.29b)
RoCE = 4.21% (EBIT 176.2m / Capital Employed (Equity 3.29b + L.T.Debt 892.7m))
RoIC = 2.65% (NOPAT 139.2m / Invested Capital 5.25b)
WACC = 6.18% (E(12.3b)/V(14.0b) * Re(6.53%) + D(1.69b)/V(14.0b) * Rd(4.59%) * (1-Tc(0.21)))
Discount Rate = 6.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.03 | Cagr: 30.77%
[DCF] Terminal Value 77.97% ; FCFF base≈218.3m ; Y1≈250.3m ; Y5≈368.4m
[DCF] Fair Price = 18.38 (EV 5.54b - Net Debt 1.54b = Equity 4.01b / Shares 218.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.15 | # QB: 0
Revenue Correlation: 99.07 | Revenue CAGR: 11.31% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.16 | Chg30d=+3.23% | Revisions=-40% | Analysts=1
EPS current Year (2026-12-31): EPS=0.60 | Chg30d=-2.28% | Revisions=+25% | GrowthEPS=+43.9% | GrowthRev=+23.6%
EPS next Year (2027-12-31): EPS=0.99 | Chg30d=+15.12% | Revisions=-40% | GrowthEPS=+56.4% | GrowthRev=+14.6%
[Analyst] Revisions Ratio: -38% (up=1, down=4)